Compare SDHC & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDHC | IPSC |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.0M | 189.7M |
| IPO Year | 2023 | 2021 |
| Metric | SDHC | IPSC |
|---|---|---|
| Price | $11.23 | $2.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $14.60 | $3.50 |
| AVG Volume (30 Days) | 169.3K | ★ 1.1M |
| Earning Date | 03-11-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $971,116,000.00 | $109,164,000.00 |
| Revenue This Year | $7.71 | N/A |
| Revenue Next Year | $11.19 | N/A |
| P/E Ratio | $9.74 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $11.24 | $0.34 |
| 52 Week High | $23.50 | $2.97 |
| Indicator | SDHC | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 27.77 | 55.55 |
| Support Level | $11.24 | $0.49 |
| Resistance Level | $22.05 | $2.71 |
| Average True Range (ATR) | 1.05 | 0.25 |
| MACD | -0.10 | -0.04 |
| Stochastic Oscillator | 3.17 | 42.77 |
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.